Spinal Muscular Atrophy (SMA) Mouse Model Development Service

Accelerate Your Therapeutic Discovery! Are you currently facing challenges in preclinical validation for neurodegenerative diseases, specifically Spinal muscular atrophy (SMA), leading to prolonged drug development cycles? Our specialized SMA mouse model services help you accelerate drug discovery and obtain high-quality preclinical data through advanced genetic engineering and comprehensive phenotypic characterization.

SMA Mouse Models: A Foundation for Breakthroughs. SMA is a severe neurodegenerative disorder caused by insufficient Survival Motor Neuron (SMN) protein. Mouse models are indispensable tools in SMA research, faithfully recapitulating key aspects of the human disease. They enable the elucidation of disease mechanisms, identification of therapeutic targets, and crucial preclinical testing of novel treatments, accelerating the journey towards effective therapies.

How Our SMA Mouse Models Can Assist Your Project

At Creative Biolabs, we provide tailored solutions for your SMA research, delivering precise, reliable data that drives your therapeutic programs forward. Our expertise ensures you gain critical insights into disease mechanisms and robust validation of your drug candidates.

Discover How We Can Help - Request a Consultation.

Workflow:

Required Starting Materials: To initiate a project, clients typically provide 2-3 concrete examples of the types of information or materials needed. This includes:
- Detailed project objectives and desired outcomes.
- Specific therapeutic compounds or genetic constructs for testing.
- Relevant preliminary data or existing research findings.

Fig.1 Workflow of our Spinal Muscular Atrophy (SMA) Mouse Models Development Services Can Assist Your Project. (Creative Biolabs Original)

Final Deliverables: Upon completion of the service, clients receive:
- A detailed, comprehensive study report with all raw and analyzed data.
- High-resolution images from histopathological and molecular analyses.
- Recommendations for next steps and future research directions.
Estimated Timeframe: The typical timeframe for this service ranges from 12 to 24 weeks, depending on the complexity of the study design, the specific SMA model utilized, and the duration of therapeutic intervention required.

Why Choose Us?

CBL stands at the forefront of SMA mouse model research, offering unparalleled expertise, state-of-the-art facilities, and a proven track record of success. Our unique features and advantages ensure your project is handled with the utmost scientific rigor and efficiency.

Experience the Advantage - Get a Quote Today.

Customer Reviews:

"Unmatched Precision! Using CBL's SMA mouse models in our research has significantly improved the precision of our preclinical efficacy studies. Their detailed pathological analysis of motor neuron survival and muscle integrity provided insights we couldn't achieve with other models, directly informing our lead compound selection. The team's responsiveness and scientific depth were exceptional." - [2024], Mar** S*.

"Accelerated Validation! CBL's workflow for therapeutic administration and phenotypic characterization facilitated a rapid and robust validation of our novel small molecule. The comprehensive data package, including both behavioral and molecular endpoints, was instrumental in demonstrating the compound's potential. Their expertise in handling severe SMA models was particularly valuable, allowing us to see significant survival benefits." - [2023], Pat** K*.

"Reliable & Reproducible! We chose CBL for their reputation in generating humanized SMN2 models. The consistency and reproducibility of their model phenotypes across different cohorts were outstanding, providing a solid foundation for our long-term studies on chronic SMA progression. This reliability allowed us to confidently compare our therapeutic interventions against established benchmarks." - [2024], Chr** L*.

Spinal Muscular Atrophy (SMA) Mouse Models

With over two decades of experience at the forefront of neurodegenerative disease research, CBL leverages unparalleled scientific expertise and state-of-the-art platforms to provide comprehensive solutions for SMA therapeutic development.

Models	Description
Severe SMA Models	e.g., SMNΔ7, Smn-/-;SMN2. These models carry a severe phenotype, often exhibiting a very short lifespan (typically 5-20 days post-birth), muscle weakness, motor neuron loss, and growth retardation, closely mirroring severe human SMA (Type 0/I).
Intermediate/Mild SMA Models	e.g., SMN2+/+; SMNΔ7; Smn-/-; SMN2. These models are engineered to have more copies of the human SMN2 gene, leading to a milder phenotype and a longer lifespan, making them suitable for studying chronic disease progression and the long-term effects of therapeutics.
Humanized SMN2 Models	hese models incorporate the full human SMN2 gene locus, providing a more faithful representation of the human genetic context.
Conditional Knockout Models	These advanced models allow for the tissue-specific or inducible deletion of the Smn gene, providing insights into the role of SMN protein in different cell types and at various stages of development

SMA mouse models are instrumental across the entire spectrum of preclinical research:

Pathogenesis Elucidation: By studying the onset and progression of symptoms, motor neuron degeneration, and muscle pathology in these models, researchers gain a deeper understanding of the disease mechanisms, including axonal defects, neuromuscular junction abnormalities, and cellular stress responses.
Therapeutic Development:
- Antisense Oligonucleotides (ASOs): Models are used to test ASOs designed to correct SMN2 splicing, leading to increased production of full-length SMN protein.
- Gene Therapy: Preclinical studies in mouse models have been pivotal in the development of AAV-mediated gene therapies that deliver a functional copy of the SMN1 gene.
- Small Molecules: These models are used to screen and validate small molecules that can modulate SMN protein levels, enhance SMN function, or target downstream pathways affected by SMN deficiency.
Biomarker Discovery and Validation: Mouse models enable the identification of potential biomarkers (e.g., neurofilament light chain, creatine kinase) in blood, CSF, or tissue that can reflect disease activity and therapeutic response, crucial for clinical trial design.
Translational Research: Data generated from SMA mouse models directly informs the design of human clinical trials, guiding patient selection, dose escalation, and outcome measure selection, thereby accelerating the translation of promising therapies from bench to bedside.

What We Can Offer

At CBL, our commitment to advancing SMA therapeutics is reflected in the comprehensive and customizable services we provide for SMA mouse models. We empower biology experts like you with the tools and expertise needed to accelerate discovery and validate novel treatments.

Comprehensive One-Stop Preclinical Solutions: From initial model generation and meticulous characterization to large-scale, robust efficacy studies, CBL offers an integrated platform to support your entire preclinical pipeline.
Expert Model Generation & Characterization: Benefit from our efficient processes in generating and comprehensively characterizing a wide array of SMA mouse models, including humanized variants and conditional knockouts, precisely tailored to your research.
Scalable Study Capabilities: Our facilities and expertise allow for the management of large cohorts and multiple SMA mouse models concurrently, ensuring your studies are powered for statistically significant and reliable outcomes.
Rigorous Quality by Design (QbD) Approach: We implement a well-established quality system, incorporating QbD principles into every study design and execution, ensuring the highest standards of scientific rigor and data integrity.
Regulatory-Ready Data Generation: Our studies are conducted under stringent quality standards, providing data that supports your regulatory submissions and accelerates your path to clinical trials.
Guaranteed Model Consistency & Stability: We ensure the genetic stability and phenotypic consistency of our SMA mouse colonies, providing reliable and reproducible results across all your preclinical investigations.
Optimized Genetic Engineering & Phenotyping: Leverage our expertise in optimizing genetic modifications and model characteristics to best suit your unique research objectives, maximizing the translational relevance of your findings.
Flexible & Customized Study Designs: We offer adaptable study designs, including acute and chronic treatment paradigms, to precisely meet your diverse research needs and therapeutic development timelines.
Advanced Analytical & Quality Control Tools: Our commitment to precision is underscored by the utilization of high-standard quality control tools for accurate quantification and evaluation of all experimental endpoints.

Related Services

To further support your neurodegenerative disease research, CBL offers a suite of complementary services:

Ready to advance your SMA research? Contact our team today for detailed information and to discuss your project. We are eager to collaborate and help you achieve your scientific milestones.

Contact Our Team for More Information and to Discuss Your Project.

For Research Use Only. Not For Clinical Use.

In Vivo Services

Hot Products

Antibodies

Cells

Kits

Tracers

Gene Therapy Tools

Biospecimens

Cell Assay Reagents